Primary immunodeficiency disease (PIDD) comprises group of rare disorders, mostly genetic in nature, wherein a part of the immune system is missing or does not function correctly. The symptoms include a markedly increased vulnerability to serious illness and infection, organ damage and the immune system also attacking the body’s own tissues and cells. Primary Immunodeficiency is largely treated with therapies derived from human plasma, and in the most severe forms, replacement of stem cells. The report on global primary immunodeficiency diseases market by treatment has been studied and assessed for four prominent categories: Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem cells and gene therapy and others. The market for others provide a cumulative estimation for vaccines and nutritional supplement.
Browse Full Report With TOC:- http://www.transparencymarketresearch.com/primary-immunodeficiency-disease-market.html
Immunoglobulin (Ig) has been used to treat hypogammaglobulinaemia for more than two decades or more. Recently, it has also been used to treat diseases such as combined immunodeficiency and partial antibody deficiency. Ig are as a replacement therapy are usually administered via two prominent modes i.e. intravenous and subcutaneous which has well demonstrated their efficacy and safety in primary immunodeficiency (PIDD) treatment. A recent survey published by the Medical Insights Groups in 2014 illustrated that 54% of home-based Ig are delivered through SC, whereas only 46% are considered for IV in the U.S. Demand for SC is growing rapidly especially among school going children as it can be delivered in home settings with a one hour infusion, whereas venous access requires three to four hour infusion for IVIG.
Long-term prophylactic antibiotics are being widely implemented as primary or adjunctive therapy for PIDD treatment. This practice has transformed clinical outcomes in the setting of chronic granulomatous disease, complement deficiencies, Wiskott-Aldrich syndrome, hyper IgE syndrome. Patients with PIDD are often prescribed longer and stronger courses of antibiotics than usual. This could mean courses of 14 days or sometimes longer. The reason for this is to prevent relapse or recurrence of infection. Some of the commonly used antibiotics in PIDD treatment include penicillin, cephalosporins, macrolides, fluoroquinolones, sulfonamides, tetracyclines, and aminoglycosides.
Hematopoietic stem cell treatment (HSCT) successfully cures a wide range of primary immunodeficiency disorders. Advances in medical science has led to an improved survival rate and better quality of life, especially with respect to orphan diseases. HSCT owing to its better outcomes is now increasingly practiced for treating non-SCID based patients suffering from diseases such as Wiskott-Aldrich syndrome, Omenn syndrome, CD40 ligand deficiency and others. Gene therapy has been used to treat patients with SCID due to adenosine deaminase (ADA) deficiency, X-linked severe combined immunodeficiency, chronic granulomatous disease, and Wiskott-Aldrich syndrome. Various laboratories across the world are working at modifications of the viral vectors in order to improve their safety. Stem cells and gene therapy market is expected to be the fastest growing segment during the forecast tenure owing to increasing number of clinical trial and research studies and significant reduction in mortality and morbidity in past few years.
Lack of adequate nutrition can also lead to many illnesses including infections for which the individual with primary immunodeficiency disease is already at risk. Vitamin supplements include vitamins A, C, and E, which are all valuable parts of the body's defense system aid in increasing the production of healthy white blood cells and to fight infection.
The report offers a detailed description behind this high growth and outlines a possible growth trajectory for other segments of PIDD market such as by diseases, by test and by geography. The market study also profiled some of the leading companies operating in primary immunodeficiency diseases market across the globe. These encompasses Baxter International, Inc., Biotest AG, CSL Behring LLC, Bio Products Laboratory Ltd., Kedrion S.p.A., LFB S.A., Octapharma AG and Grifols S.A.
The global primary immunodeficiency diseases market is segmented into the following categories:
Global Primary Immunodeficiency Diseases Market, by Disease
Antibody Deficiency
Agammaglobulinaemia ((X-Linked and Autosomal Recessive)
Common Variable Immune Deficiency
Selective IgA Deficiency
IgG Subclass Deficiency
Others
Cellular Immunodeficiency
Ataxia Telangiectasia
Hyper IgM Syndromes
Wiskott-Aldrich Syndrome
DiGeorge Syndrome
Others
Innate Immune Disorders
Complement Deficiencies
Hyper IgE Syndrome
Others
Global Primary Immunodeficiency Diseases Market, by Test
Blood Test
Prenatal Testing
Global Primary Immunodeficiency Diseases Market, by Treatment
Immunoglobulin Replacement Therapy
Antibiotic Therapy
Stem cell and Gene Therapy
Others
Request For Sample Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=3137
About Us:-
Transparency Market Research (TMR) is a next-generation provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.
Contact Us:-
Mr.Sudip.S
Transparency Market Research
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
Email: sales@transparencymarketresearch.com
Browse Full Report With TOC:- http://www.transparencymarketresearch.com/primary-immunodeficiency-disease-market.html
Immunoglobulin (Ig) has been used to treat hypogammaglobulinaemia for more than two decades or more. Recently, it has also been used to treat diseases such as combined immunodeficiency and partial antibody deficiency. Ig are as a replacement therapy are usually administered via two prominent modes i.e. intravenous and subcutaneous which has well demonstrated their efficacy and safety in primary immunodeficiency (PIDD) treatment. A recent survey published by the Medical Insights Groups in 2014 illustrated that 54% of home-based Ig are delivered through SC, whereas only 46% are considered for IV in the U.S. Demand for SC is growing rapidly especially among school going children as it can be delivered in home settings with a one hour infusion, whereas venous access requires three to four hour infusion for IVIG.
Long-term prophylactic antibiotics are being widely implemented as primary or adjunctive therapy for PIDD treatment. This practice has transformed clinical outcomes in the setting of chronic granulomatous disease, complement deficiencies, Wiskott-Aldrich syndrome, hyper IgE syndrome. Patients with PIDD are often prescribed longer and stronger courses of antibiotics than usual. This could mean courses of 14 days or sometimes longer. The reason for this is to prevent relapse or recurrence of infection. Some of the commonly used antibiotics in PIDD treatment include penicillin, cephalosporins, macrolides, fluoroquinolones, sulfonamides, tetracyclines, and aminoglycosides.
Hematopoietic stem cell treatment (HSCT) successfully cures a wide range of primary immunodeficiency disorders. Advances in medical science has led to an improved survival rate and better quality of life, especially with respect to orphan diseases. HSCT owing to its better outcomes is now increasingly practiced for treating non-SCID based patients suffering from diseases such as Wiskott-Aldrich syndrome, Omenn syndrome, CD40 ligand deficiency and others. Gene therapy has been used to treat patients with SCID due to adenosine deaminase (ADA) deficiency, X-linked severe combined immunodeficiency, chronic granulomatous disease, and Wiskott-Aldrich syndrome. Various laboratories across the world are working at modifications of the viral vectors in order to improve their safety. Stem cells and gene therapy market is expected to be the fastest growing segment during the forecast tenure owing to increasing number of clinical trial and research studies and significant reduction in mortality and morbidity in past few years.
Lack of adequate nutrition can also lead to many illnesses including infections for which the individual with primary immunodeficiency disease is already at risk. Vitamin supplements include vitamins A, C, and E, which are all valuable parts of the body's defense system aid in increasing the production of healthy white blood cells and to fight infection.
The report offers a detailed description behind this high growth and outlines a possible growth trajectory for other segments of PIDD market such as by diseases, by test and by geography. The market study also profiled some of the leading companies operating in primary immunodeficiency diseases market across the globe. These encompasses Baxter International, Inc., Biotest AG, CSL Behring LLC, Bio Products Laboratory Ltd., Kedrion S.p.A., LFB S.A., Octapharma AG and Grifols S.A.
The global primary immunodeficiency diseases market is segmented into the following categories:
Global Primary Immunodeficiency Diseases Market, by Disease
Antibody Deficiency
Agammaglobulinaemia ((X-Linked and Autosomal Recessive)
Common Variable Immune Deficiency
Selective IgA Deficiency
IgG Subclass Deficiency
Others
Cellular Immunodeficiency
Ataxia Telangiectasia
Hyper IgM Syndromes
Wiskott-Aldrich Syndrome
DiGeorge Syndrome
Others
Innate Immune Disorders
Complement Deficiencies
Hyper IgE Syndrome
Others
Global Primary Immunodeficiency Diseases Market, by Test
Blood Test
Prenatal Testing
Global Primary Immunodeficiency Diseases Market, by Treatment
Immunoglobulin Replacement Therapy
Antibiotic Therapy
Stem cell and Gene Therapy
Others
Request For Sample Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=3137
About Us:-
Transparency Market Research (TMR) is a next-generation provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.
Contact Us:-
Mr.Sudip.S
Transparency Market Research
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
Email: sales@transparencymarketresearch.com
